Wockhardt Zaynich FDA Approval Cracks $9B Antibiotic Market

Wockhardt’s Zaynich FDA approval has made history as the first New Chemical Entity fully developed by an Indian pharma company to receive a US FDA nod. With an 89% efficacy rate against drug-resistant Gram-negative bacteria and eyes on a $9 billion antibiotics market, India’s pharma ambitions just got a whole lot louder.